trial

A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males

NCTId NCT02935725
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 22 (actual)
Sponsored by Autifony Therapeutics Limited
Primary completion 2017-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
22 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2016-10
Primary completion
2017-11
Eligibility
MALE · 18 Years · 45 Years

Interventions & indications

Drugs
Low dose AUT00206 800mgHigh dose AUT00206 2000 mgKetamine

Sponsors

Autifony Therapeutics LimitedLead Sponsor
University of ManchesterCollaborator

Investigators

1
Bill Deakin, ProfessorPrincipal Investigator

Sites

1 total
London, United Kingdom

Facts & assertions

4 sourced
Enrollment
22
Phase
PHASE1
Primary Completion Date
2017-11
Status
COMPLETED
relationships
The graph out of here
drug
Low dose AUT00206 800mg
drug
High dose AUT00206 2000 mg
drug
Ketamine
drug
lead_sponsor
Autifony Therapeutics Limited
company
collaborator
University of Manchester
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Bill Deakin, Professor
person